Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.34)
# 355
Out of 5,058 analysts
110
Total ratings
51.09%
Success rate
18.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $90 → $148 | $96.91 | +52.72% | 7 | Nov 13, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $105 → $114 | $103.15 | +10.52% | 9 | Nov 10, 2025 | |
| GBIO Generation Bio Co. | Maintains: Buy | $9 → $10 | $5.18 | +93.05% | 3 | Aug 18, 2025 | |
| PASG Passage Bio | Maintains: Buy | $260 → $67 | $7.88 | +750.25% | 7 | Aug 14, 2025 | |
| GUTS Fractyl Health | Maintains: Buy | $12 → $6 | $1.33 | +351.13% | 1 | Aug 14, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $11 → $14 | $4.01 | +249.13% | 11 | Aug 13, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $136 → $128 | $31.86 | +301.76% | 9 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $424 → $411 | $421.03 | -2.38% | 9 | Aug 6, 2025 | |
| WVE Wave Life Sciences | Initiates: Buy | $19 | $6.88 | +176.16% | 1 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $390 → $415 | $460.76 | -9.93% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $2.88 | +247.22% | 9 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $54 | $8.24 | +555.34% | 6 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $66 | $6.04 | +992.72% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $6 | $1.19 | +404.20% | 6 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $148 → $150 | $16.39 | +815.19% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $52.56 | +59.82% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $128.07 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $120 → $240 | $5.98 | +3,913.38% | 4 | Jul 23, 2019 |
Palvella Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $90 → $148
Current: $96.91
Upside: +52.72%
Rhythm Pharmaceuticals
Nov 10, 2025
Maintains: Buy
Price Target: $105 → $114
Current: $103.15
Upside: +10.52%
Generation Bio Co.
Aug 18, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $5.18
Upside: +93.05%
Passage Bio
Aug 14, 2025
Maintains: Buy
Price Target: $260 → $67
Current: $7.88
Upside: +750.25%
Fractyl Health
Aug 14, 2025
Maintains: Buy
Price Target: $12 → $6
Current: $1.33
Upside: +351.13%
Taysha Gene Therapies
Aug 13, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $4.01
Upside: +249.13%
Ultragenyx Pharmaceutical
Aug 8, 2025
Maintains: Buy
Price Target: $136 → $128
Current: $31.86
Upside: +301.76%
Vertex Pharmaceuticals
Aug 6, 2025
Maintains: Hold
Price Target: $424 → $411
Current: $421.03
Upside: -2.38%
Wave Life Sciences
Aug 4, 2025
Initiates: Buy
Price Target: $19
Current: $6.88
Upside: +176.16%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Buy
Price Target: $390 → $415
Current: $460.76
Upside: -9.93%
Jul 25, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $2.88
Upside: +247.22%
Jun 3, 2025
Maintains: Buy
Price Target: $74 → $54
Current: $8.24
Upside: +555.34%
May 13, 2025
Maintains: Buy
Price Target: $68 → $66
Current: $6.04
Upside: +992.72%
Mar 13, 2025
Maintains: Buy
Price Target: $18 → $6
Current: $1.19
Upside: +404.20%
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $16.39
Upside: +815.19%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $52.56
Upside: +59.82%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $128.07
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $120 → $240
Current: $5.98
Upside: +3,913.38%